Semaglutide, a long-acting glucagon-like receptor 1 (GLP1R) agonist currently approved for treatment of type 2 diabetes and obesity23,24, has been reported to increase resolution of NASH without improving fibrosis stage in a proof-of-concept clinical trial25. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.